Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

@article{Maerken2009AntitumorAO,
  title={Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.},
  author={Tom M A Van Maerken and Liesbeth Ferdinande and Jasmien Taildeman and Irina Lambertz and Nurten Yigit and Liesbeth Vercruysse and Ali Rihani and Martin Michaelis and Jindrich Cinatl and Claude A. Cuvelier and J. -C. Marine and Anne De Paepe and Marc E. Bracke and Frank Speleman and Jo Vandesompele},
  journal={Journal of the National Cancer Institute},
  year={2009},
  volume={101 22},
  pages={1562-74}
}
BACKGROUND Restoring p53 function by antagonizing its interaction with the negative regulator MDM2 is an appealing nongenotoxic approach to treating tumors with wild-type p53. Mutational inactivation of p53 is rare in neuroblastoma tumors at diagnosis and occurs in only a subset of multidrug-resistant neuroblastomas. METHODS The antiproliferative and cytotoxic effect of nutlin-3, a small-molecule MDM2 antagonist, was examined in chemosensitive (UKF-NB-3) and matched chemoresistant… CONTINUE READING